PRO-2000, an antimicrobial gel for the potential prevention of HIV infection.

Abstract

Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. The company is also investigating its potential to prevent the transmission of other sexually transmitted diseases. In February 2005, Indevus launched a pivotal phase III trial for the prevention of HIV infection in women. At that time, further phase III trials in 12,000 African women were scheduled to begin in 2005. A second phase III trial began for the prevention of sexually transmitted infections, including HIV, herpes, Chlamydia and gonorrhea, in Africa in October 2005.

• Authors: Patricia S Fletcher, Robin J Shattock
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 2 Pg. 189-200 (Feb 2008) ISSN: 1472-4472 [Print] England
• PMID: 18246522 (Publication Type: Journal Article)

Chemical References

• Anti-HIV Agents
• Naphthalenesulfonates
• PRO 2000
• Polymers
• Vaginal Creams, Foams, and Jellies

Topics

• Animals
• Anti-HIV Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Drug Evaluation, Preclinical
• Female
• HIV Infections (prevention & control)
• HIV-1 (drug effects)
• Humans
• Naphthalenesulfonates (chemistry, pharmacology, therapeutic use)
• Patents as Topic
• Polymers (chemistry, pharmacology, therapeutic use)
• Structure-Activity Relationship
• Vaginal Creams, Foams, and Jellies